Chemo Experts, the easiest way to learn about cancer treatment
Find a Treatment:
Cancer Types
or
Treatments

Treatment Name: Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®) + Paclitaxel (Taxol®) + Carboplatin

Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®) + Paclitaxel (Taxol®) + Carboplatin is a Treatment Regimen for Lung Cancer, Non-Small Cell Lung Cancer (NSCLC)

Thank you for visiting our Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®) + Paclitaxel (Taxol®) + Carboplatin page.

While we work on uploading the pages that matter to you most, we hope that links to journal article references for Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®) + Paclitaxel (Taxol®) + Carboplatin shown below will prove useful in the meantime.

Thank you for your continued support!

Sincerely,
The ChemoExperts Team

References

1) Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.

Created: March 18, 2019 Updated: March 18, 2019

What is Lung Cancer, Non-Small Cell Lung Cancer (NSCLC)?

What is Non-Small Cell Lung Cancer?
A disease of the tissue found in the lung.  Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Known causes include smoking and exposure to environmental toxins.  The stage of NSCLC can vary at diagnosis and throughout treatment.  Stages include stage I, II, III, and IV.  The effectiveness of the treatment may depend upon the stage at diagnosis.

NOTE: Treatment Options listed below are not all-inclusive. Other treatments may be available. ChemoExperts provides drug information and does not recommend any one treatment over another. Only your Doctor can choose which therapy is appropriate for you.

Common Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin

Induction:

  • Atezolizumab 1,200 mg intravenous (I.V.) infusion over 60 minutes on Day 1
  • Bevacizumab 15 mg/kg I.V. infusion over 90 minutes on Day 1 of Cycle 1
    • then over 60 minutes for Cycle 2, if no infusion reactions occur
    • then over 30 minutes for Cycles 3 and on, if no infusion reactions occur
  • Paclitaxel 200 mg/m2 I.V. infusion over 3 hours on Day 1
  • Carboplatin AUC 6 I.V. infusion over 30 minutes on Day 1

Maintenance:

  • Atezolizumab 1,200 mg intravenous (I.V.) infusion over 60 minutes on Day 1
  • Bevacizumab 15 mg/kg I.V. infusion over 30 minutes on Day 1

Note: atezolizumab and bevacizumab may both be given during the maitenance phase or only one of them may be given